NEWS

We inform you about the current business development of HAEMATO AG and about our investor relations activities.

IFRS Third-Quarter 2018 Results

IFRS Third-Quarter 2018 Results

In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 million...

read more
Half Year Report 2018

Half Year Report 2018

In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million. EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8). The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is therefore also...

read more
IFRS results Q1 2018

IFRS results Q1 2018

HAEMATO AG is a listed pharmaceutical company focusing on the growth markets of high-priced special pharmaceuticals from the indication areas oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the...

read more
Annual Report 2017

Annual Report 2017

HAEMATO AG is a listed pharmaceutical company with a focus on the growth markets of special pharmaceuticals, primarily in the high-priced indication areas of oncology and HIV as well as rheumatism, neurology and cardiovascular diseases. HAEMATO AG had a...

read more
2017: Preliminary IFRS results

2017: Preliminary IFRS results

2017: According to the preliminary IFRS results, Haemato AG increased its sales by 5.2% to EUR 289.9 million. In 2017, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved an IFRS group turnover of €289,9m (previous year: €275.6m), an operating result (EBIT)...

read more

HAEMATO AG

HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany

Phone: +49-30 897 30 86 70
Telefax: +49-30 897 30 86 79
E-Mail: info@haemato.ag